

Ivana Kuzminac<sup>1</sup>, Andrea Nikolić<sup>1</sup>, Marina Savić<sup>1</sup>, Jovana Ajduković<sup>1</sup>, Sofija Bekić<sup>1</sup>, Anđelka Čelić<sup>2</sup>, Dimitar Jakimov<sup>3</sup>, Tijana Šestić<sup>1</sup>, Marija Sakač<sup>1</sup>

<sup>1</sup>University of Novi Sad, Faculty of Sciences, Department of Chemistry, Biochemistry and Environmental Protection, Trg Dositeja Obradovića 3, 21000 Novi Sad, Serbia,

<sup>2</sup>University of Novi Sad, Faculty of Sciences, Department of Biology and Ecology, Trg Dositeja Obradovića 2, 21000 Novi Sad, Serbia, <sup>3</sup>Oncology Institute of Vojvodina, Faculty of Medicine, University of Novi Sad, Put Dr Goldmana 4, 21204 Sremska Kamenica, Serbia.

Corresponding author: ivana.kuzminac@dh.uns.ac.rs

**KEYWORDS:** lactone, SwissADME, cytotoxicity, estrogen receptors, androgen receptor.

## INTRODUCTION:

Breast cancer is the most commonly occurring form of cancer in women and the second most common cancer overall. The growth of around 80% of breast cancers is stimulated by estrogens that bind to receptors in tumor cells. For the treatment of these cancers, antiestrogens and inhibitors of the enzyme aromatase are used. Some of these pharmaceuticals have steroid structures and were used in this work for the design of novel steroid derivatives as potential antitumor compounds.

## OBJECTIVES:

In this paper, we report the synthesis of two new 19-modified steroidal derivatives **6** and **7** (Scheme 1). *In silico* ADME properties of these compounds were tested using SwissADME online tool (Figure 1 and 2). Novel steroid derivatives were tested for relative affinity to the ligand-binding domains of estrogen receptors (ER $\alpha$  and ER $\beta$ ) and androgen receptor (AR) (Figure 3). In addition, these compounds were tested for their cytotoxic activity against six human tumor cell lines and one healthy human cell line (Table 1).

## METHOD / DESIGN:

- Five-step synthesis from 3 $\beta$ -acetoxy-5 $\alpha$ -bromo-6 $\beta$ -hydroxy-17-oxa-17a-homoandrost-16-one (Scheme 1);
- *In silico* ADME - Analysis of Bioavailability Radars (Figure 2) and the BOILED-Egg model (Figure 1);
- Receptor binding - a fluorescence assay in yeast (Figure 3);
- Cytotoxicity - MTT assay, cell lines: MCF-7 (human breast adenocarcinoma ER+), MDA-MB-231 (human breast adenocarcinoma ER-), PC-3 (prostate cancer AR-), HeLa (cervical cancer), HT-29 (colon cancer), A549 (lung adenocarcinoma), MRC-5 (healthy fetal lung fibroblasts).

## RESULTS:





Figure 1. Bioavailability Radars of compounds 6 and 7




Figure 2. the BOILED-Egg model of compounds 6 and 7




Figure 3. Results from the ligand binding assay for 6 and 7

Table 1. Cytotoxic activity of compounds 6 and 7

Comp.	IC <sub>50</sub> (μM)						
	MCF-7	MDA-MB-231	PC-3	HeLa	HT-29	A549	MRC-5
6	20.27	55.90	>50	>50	>50	15.62	>50
7	1.71	>50	>50	>50	>50	>50	>50
cisplatin	1.60	2.64	4.56	2.10	4.10	3.20	0.24
formestane	>50	19.61	26.37	3.36	>50	38.59	>50

## CONCLUSIONS:

Compounds **6** and **7** have shown good results in *in silico* ADME testing, meaning that they possess drug-like properties. Compound **7** showed high cytotoxicity and selectivity for MCF-7 cell line.

## ACKNOWLEDGEMENT

The authors acknowledge financial support of Provincial Secretariat for Higher Education and Scientific Research of the Autonomous Province of Vojvodina [Project: Development of steroid derivatives of potential biomedical importance, No. 142-451-2309/2021-01].